Sleep quality and other patient‐reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open‐label Phase IIIB trial

Strober, Bruce; Sobell, Jeffrey M.; Duffin, Kristina Callis; Bao, Yanjun; Guérin, Annie; Yang, Hongbo; Goldblum, Orin; Okun, Martin; Mulani, P.M.

doi:10.1111/bjd.12000

Cited by 58 publications

(71 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Further, in another study where telephone and e-mail surveys were conducted, Callis Duffin et al [11] found that 49.5% of patients with psoriasis claimed that their sleep was affected negatively by psoriasis at least once a month. Our results were in accordance with the results of previous studies showing sleep disturbances in patients with psoriasis [3,12,13]. The common conclusion in these studies was that understanding the origin of comorbidities, including sleep problems, in patients with psoriasis may help improve daily living and future treatment of the disease [3].…”

Section: Discussionsupporting

confidence: 92%

“…Thus, sleep disturbance should be considered as a risk factor for the development of psoriasis [14]. Our study presents additional confirmation that besides sleep disturbances, patients with psoriasis have substantially impaired sleep quality compared with general healthy people [11,12,15].…”

Section: Discussionsupporting

confidence: 67%

“…The impairment of these components was also correlated with disease severity. In another study that evaluated sleep quality by another measurement in patients with psoriasis, the PASI was found to be a significant predictor of the daytime somnolence and sleep adequacy components of sleep quality [12]. In spite of different sleep quality tools, our results may be considered to be parallel to these results.…”

Section: Discussionsupporting

confidence: 61%

“…In previous studies, there were different results on the relationship between sleep impairment and disease severity in these patients [3,12,16]. Koo [16] showed that increased psoriasis severity is an associated factor in sleep impairment.…”

Section: Discussionmentioning

confidence: 95%

“…Koo [16] showed that increased psoriasis severity is an associated factor in sleep impairment. However, in another study, it was concluded that total work productivity and dermatology-specific healthrelated QoL as subjective symptoms seemed to be more significantly correlated to sleep disturbance than objective psoriasis signs such as the PASI [12]. This may be due to the measurement of disease severity in psoriasis, which has been considered as a contentious evaluation [2].…”

Section: Discussionmentioning

confidence: 99%

See 4 more Smart Citations

Sleep Quality and its Association with Disease Severity in Psoriasis

Melikoğlu¹

2017

Eurasian J Med

View full text Add to dashboard Cite

Objective: The main purpose of this research was to crosscheck sleep quality in patients with psoriasis with that in healthy individuals and to evaluate a possible relationship between sleep quality and disease severity in these patients. Materials and Methods:Fifty-eight patients with plaque psoriasis and 58 age-and gender-matched healthy individuals were included. The Psoriasis Area and Severity Index (PASI) scoring method was used to assess the disease severity in patients with psoriasis. The sleep quality of the participants was evaluated by the Pittsburgh Sleep Quality Index (PSQI). The sleep quality scores of the patients with psoriasis were compared to those of healthy controls. Pearson' s correlation test and independent samples t-test and were used to interpret the data.Results: The mean disease duration was 11.1±7.4 years (mean±standard deviation), and the mean PASI was 14.1±5.3. In total, 60% of the patients with psoriasis (n=35) experienced poor sleep quality, and this frequency was considerably higher in the patients with psoriasis than in the healthy controls (p<0.000). Further, the mean PSQI in the patients with psoriasis (7.01±41.4) was higher than that in the healthy controls (4.18±2.76, p=0.000). The scores of daytime dysfunction, habitual sleep efficiency, and subjective sleep quality, which are the three components of sleep quality, were considerably higher in the patients with psoriasis than in the healthy controls (p=0.007, p=0.032, and p=0.034, respectively). Conclusion:Our results showing impaired sleep quality and its association with disease severity in patients with psoriasis may contribute to the management of psoriasis.Keywords: Psoriasis, sleep quality, psoriasis severity ÖZ Amaç: Sağlıklı kontrollerle, psöriazis hastalarında uyku kalitesini karşılaştırmak ve uyku kalitesi ve bu hastalarda hastalık şiddeti arasında olası bir ilişkiyi değerlendirmekti.Gereç ve Yöntem: Psöriazis hastalığı olan elli sekiz hasta yaş ve cinsiyet uyumlu 58 sağlıklı kontrol bu çalışmaya dahil edildi. Psöriazis alan ve şiddet indeksi (PASİ) hastalığın şiddetini değerlendirmek için kullanıldı. Katılımcıla-rın uyku kalitesi 'Pittsburgh uyku kalite indeksi' ile değerlendirildi. Psöriazis hastalığı olan hastaların uyku kalitesi puanları sağlıklı kontrol ile karşılaştırıldı. Bağımsız t testi ve Pearson korelasyon testi istatistiki değerlendirme için kullanıldı.Bulgular: Ortalama hastalık süresi 11,1±7,4 yıl (ortalama±standart sapma) ve ortalama PASI 14,1±5,3 olarak değerlendirildi. Psöriazis hastalarının %60'ında (n=35) uyku kalitesi düşüktü ve bu sıklık hastalarda sağlık-lı kontrollere göre anlamlı derecede yüksekti (p<0,000). Aynı zamanda hastalar için ortalama PSQI skoru (7,01±41,4) sağlıklı kontrollerden daha yüksekti (4,18±2,76; p=0,000). Uyku kalitesinin üç bileşeninin skorları; subjektif uyku kalitesi, alışılagelmiş uyku etkinliği ve günlük disfonksiyonu, psöriazisli hastalarda sağlıklı kontrollere göre anlamlı derecede yüksekti (sırasıyla p=0,034, p=0,032 ve p=0,007).Sonuç: Sonuç olarak, Psöriazi...

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 67%

Section: Discussionsupporting

confidence: 61%

Section: Discussionmentioning

confidence: 95%

Section: Discussionmentioning

confidence: 99%

See 3 more Smart Citations

Sleep Quality and its Association with Disease Severity in Psoriasis

Melikoğlu¹

2017

Eurasian J Med

View full text Add to dashboard Cite

show abstract

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis

Sbidian

Chaimani

García‐Doval

et al. 2017

Cochrane Database of Systematic Reviews

267

309

View full text Add to dashboard Cite

Our review shows that compared to placebo, the biologics ixekizumab, secukinumab, brodalumab, guselkumab, certolizumab, and ustekinumab are the best choices for achieving PASI 90 in people with moderate to severe psoriasis on the basis of moderate- to high-certainty evidence. At class level, the biologic treatments anti-IL17, anti-IL12/23, anti-IL23, and anti-TNF alpha were significantly more effective than the small molecules and the conventional systemic agents, too. This NMA evidence is limited to induction therapy (outcomes were measured between 12 to 16 weeks after randomisation) and is not sufficiently relevant for a chronic disease. Moreover, low numbers of studies were found for some of the interventions, and the young age (mean age of 44 years) and high level of disease severity (PASI 20 at baseline) may not be typical of patients seen in daily clinical practice.Another major concern is that short-term trials provide scanty and sometimes poorly reported safety data and thus do not provide useful evidence to create a reliable risk profile of treatments. Indeed, we found no significant difference in the assessed interventions and placebo in terms of SAEs. Methotrexate appeared to have the best safety profile, but as the evidence was of very low to moderate quality, we cannot be sure of the ranking. In order to provide long-term information on the safety of the treatments included in this review, it will be necessary to evaluate non-randomised studies and postmarketing reports released from regulatory agencies as well.In terms of future research, randomised trials comparing directly active agents are necessary once high-quality evidence of benefit against placebo is established, including head-to-head trials amongst and between conventional systemic and small molecules, and between biological agents (anti-IL17 versus anti-IL23, anti-IL23 versus anti-IL12/23, anti-TNF alpha versus anti-IL12/23). Future trials should also undertake systematic subgroup analyses (e.g. assessing biological-naïve patients, baseline psoriasis severity, presence of psoriatic arthritis, etc.). Finally, outcome measure harmonisation is needed in psoriasis trials, and researchers should look at the medium- and long-term benefit and safety of the interventions and the comparative safety of different agents.

show abstract

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis

Sbidian

Chaimani

García‐Doval

et al. 2020

Cochrane Database of Systematic Reviews

196

253

View full text Add to dashboard Cite

show abstract

Sleep quality and other patient‐reported outcomes improve after patients with psoriasis with suboptimal response to other systemic therapies are switched to adalimumab: results from PROGRESS, an open‐label Phase IIIB trial

Abstract: Adalimumab treatment improved sleep outcomes and other patient-reported outcomes including health-related quality of life, work productivity, daily activity and disease-related pain.

Cited by 58 publications

References 33 publications

Sleep Quality and its Association with Disease Severity in Psoriasis

Sleep Quality and its Association with Disease Severity in Psoriasis

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis

Contact Info

Product

Resources

About